id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-6646	Bernardini, Nicoletta ; Caldarola, Giacomo; Richetta, Antonio Giovanni; Esposito, Maria; Trovato, Federica; Amerio, Paolo; Morea, Edvige; Bonifati, Claudio; Graceffa, Dario; Bruni, Pier Luigi; Giordano, Domenico; Persechino, Severino; Mazzotta, Annamaria; Moretta, Gaia; Pagnanelli, Gianluca; Pallotta, Sabatino; Anedda, Jasmine; Mugheddu, Cristina; Miraglia, Emanuele; Panasiti, Vincenzo; Molinelli, Elisa; Simonetti, Oriana; Fargnoli, Maria Concetta; Peris, Ketty; Pellacani, Giovanni; Potenza, Concetta; Dattola, Annunziata	Long-term persistence with guselkumab: a 5-year multicenter retrospective study across 14 dermatology centers in Italy	2025	9	.pdf	application/pdf	5045	317	53	IL-12/23 inhibitors like ustekinumab, and IL-23 inhibitors such as guselkumab, tildrakizumab, and risankizumab have demonstrated varying levels of treatment persistence, which is an essential measure of long-term efficacy and safety and an essential feature lead- ing to patient satisfaction in real-world settings [8]. Treatment persistence is an important real-world in- dicator of therapeutic effectiveness and tolerability.	cache/dpc-6646.pdf	txt/dpc-6646.txt